GlassScriptPhysician profile
Jason M Kidd
NPI 1588824551
$12,629.60
in general payments reported to CMS, 2019-2025
9 companies · $7,209 in 2025
The $7,209 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2023: $1,417 · 2024: $3,882 · 2025: $7,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $986 · Food and Beverage: $834 · Travel and Lodging: $609 · Education: $37.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,042.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $985.50 |
| Food and Beverage | $833.84 |
| Travel and Lodging | $609.38 |
| Education | $37.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $7,231.41 | 2023-2025 | Filspari |
| Amgen INC. | $4,927.50 | 2023-2024 | Tavneos |
| Novartis Pharmaceuticals Corporation | $206.75 | 2023-2024 | |
| Akebia Therapeutics INC | $125.00 | 2024 | Vafseo, Auryxia |
| Genzyme Corporation | $65.27 | 2019 | |
| Nxstage Medical, INC. | $56.59 | 2019 | |
| Novo Nordisk INC | $17.08 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.